目的 观察苯溴马隆对痛风伴高尿酸血症的临床疗效及对血清白介素-1β(IL-1β)和核苷酸结合寡聚化结构域样受体3(NALP3)水平的影响。方法 回顾性研究2015年3月—2017年4月84例痛风伴高尿酸血症患者的临床资料。按照治疗药物的不同分为研究组与对照组,每组42例。研究组给予苯溴马隆治疗,对照组给予别嘌醇治疗。分别评估2组的临床疗效、肾功能指标及血清IL-1β和NALP3水平变化情况,并记录不良反应的发生情况。结果 研究组临床总有效率高于对照组( P <0.05)。治疗后,2组血尿素氮、血肌酐、血尿酸、IL-1β和NALP3水平均低于治疗前,且研究组低于对照组( P <0.05)。2组不良反应总发生率比较差异无统计学意义( P >0.05)。结论 采用苯溴马隆对痛风伴高尿酸血症患者治疗可以获得良好疗效,不仅能降低血尿酸水平,改善肾功能,还可以有效抑制炎性反应,且安全性较好。
Objective To observe clinical effectiveness of Benzbromarone on patients with gout associated by hyperuricemia and its effects on serum levels of interleukin-1β(IL-1β) and NACHT-LRR-PYD domains-containing proteins 3 (NALP3). Methods Clinical data of 84 patients with gout associated by hyperuricemia during March 2015 and April 2017 was retrospectively studied, and the patients were divided into study group and control group ( n =42 for each group) according to different treatment drugs. Study group was treated with Benzbromarone, while control group was treated with Allopurinol. Clinical efficacy, indexes of renal function and serum interleukin-1β(IL-1β) and neutrophilic alkaline phosphatase 3 (NALP3) levels were evaluated, and incidence rates of adverse reactions were recorded in two groups. Results The total clinical effective rate in study group was higher than that in control group ( P <0.05). After treatment, levels of blood urea nitrogen, serum creatinine, blood uric acid, IL-1β and NALP3 were significantly lower than those before treatment in two groups, and the levels in study group were significantly lower than those in control group ( P <0.05). There was no significant difference in the total incidence rate of adverse reactions between two groups ( P >0.05). Conclusion Benzbromarone may achieve good effectiveness in treatment of patients with gout associated by hyperuricemia. It can not only reduce level of serum uric acid and improve renal function, but also effectively inhibit inflammatory reaction with good safety.
Medical Journal of Beijing Military Region